secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2025-10-07T23:59:59+00:00
Accession:  0001193125-25-233581
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Achieve Life Sciences CMO/President Dr. Cindy Jacobs resigns; stays as consultant through NDA approval
--------------------------------------------------------------------------------

- Dr. Jacobs resigned as Chief Medical Officer and President effective Oct 6, 2025.
- Separation agreement includes lump-sum cash severance of $101,296 (prorated 2025 bonus).
- She will serve as consultant until first business day after FDA NDA approval for cytisinicline.
- Unvested time-based options from Jan 2023/Jan 2024 to accelerate upon consultancy end; exercise period extended to 12 months.
- Company will reimburse up to $10,000 in legal fees for negotiation of separation and consulting agreements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000119312525233581/0001193125-25-233581-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000119312525233581/achv-20251006.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-233581

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer